Drugs & Targets EMA CHMP issues positive opinions for Tevimbra for gastric or GEJ adenocarcinoma and ESCC October 25, 2024Vol.50 No.40
Climate change exacerbates cancer disparitiesAmid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem October 18, 2024Vol.50 No.39By Claire Marie Porter
ACS board member Wayne Frederick steps in as interim CEO, replacing Karen KnudsenNational search will be conducted October 18, 2024Vol.50 No.39By Paul Goldberg
Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo October 18, 2024Vol.50 No.39By McKenzie Prillaman
Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer October 18, 2024Vol.50 No.39By Jacquelyn Cobb
In Brief Flatiron Health surpasses 1,000 research publications using RWD from its de-identified patient database October 18, 2024Vol.50 No.39
In Brief USC Norris, UNMCC collaborate to create leadership development program October 18, 2024Vol.50 No.39
In Brief Cancer Grand Challenges launches global search to identify cancer’s toughest challenges October 18, 2024Vol.50 No.39
In Brief Cathy Eng named associate director of strategic relations and research partnerships at Vanderbilt-Ingram October 18, 2024Vol.50 No.39
